logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

PTC Therapeutics' Product Risdiplam Met Trial Endpoints for the Treatment of Spinal Muscular Atrophy

PTC Therapeutics Risdiplam Results for SMA PTC Therapeutics ( PTCT ) has positive results from part 2 of the SUNFISH trial evaluating the safety and efficacy of the product risdiplam . The results demonstrate that the trial has met its...

Read More

November 14, 2019

0

The molecule that enhanced the T Cells cancer treatment efficacy while preventing autoimmune diseases

Yesterday, the Stock Market skyrocketed and with it a significant number of Prohost Picks that we keep reminding ourselves are undervalued. The outperformance unveiled the interred strength of firms such as:  Illumina (ILMN), Amgen (AMGN) and   Vertex (VRTX), t...

Read More

November 8, 2018

0

Learning More About Moderna's Virtual Vaccine Day

Moderna Therapeutics Virtual Vaccine Day On April 7, 2020 Moderna Therapeutics ( MRNA ) announced that it will host its virtual Vaccine Day for analysts and investors at 8:00 a.m. EST on Tuesday, April 14th. Moderna informed that during its...

Read More

April 14, 2020

0

Excellent news about little known products and Nektar Therapeutics

The Week in Review , which we will post soon, is going to provide news that cancer patients, their parents, their oncologists and investors are anxiously waiting to hear.   The news is about studies with products demonstrating huge improvements...

Read More

November 12, 2018

0

Exelixis is Rallying Today from CheckMate-9ER Trial Results

Exelixis Rallying from CheckMate-9ER Trial Results Exelixis ( EXEL ) and Bristol-Myers Squibb ( BMY ) announced results from CheckMate-9ER , a Phase 3 pivotal trial evaluating Opdivo® (nivolumab) in combination with Cabometyx® (cabozantinib) compared to sunitinib in previously untreated...

Read More

April 20, 2020

0

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally. Currently, during the strong economic conditions, commentators attribute...

Read More

December 3, 2019

0

A great day for Exelixis

This is just to inform that Europe has approved Cabometyx ®  (cabozantinib) tablets as a monotherapy for hepatocellular carcinoma (HCC) . As you know, Cabometyx belongs to Exelixis (EXEL) . Today Exelixis announced that its partner,  Ipsen,  received approval of...

Read More

November 15, 2018

0

RegenxBio attracts more companies. Why Loxo is important to observe today

We hope you all took advantage of the Thanksgiving holiday to rest and relax. We did. In Today’s NEWS RegenxBio Offers Rocket Pharmaceuticals exclusive, worldwide, rights to adenoviral vector NAV AAV9 for the development of treatments for Danon Disease RegenxBio (RGNX)...

Read More

November 26, 2018

0

About the Prohost Portfolio Tables

Firstly, Forty-Seven and IVERIC bio  We remind that the two condemned stocks  Forty-Seven ( FTSV ) and   IVERIC bio ( ISEE ) have continued to outperform since the day they managed to prove their lead products' safety and efficacy...

Read More

December 5, 2019

0

Why Celyad stock lost today instead of gaining on good news

Celyad (CYAD) is still a clinical-stage biopharmaceutical company developing advanced or improved CAR-T cell-based therapies. Today, Celyad announced that the first patient has received an injection in Phase 1 of the  alloSHRINK clinical trial,  evaluating its non-gene edited allogeneic CAR-T...

Read More

November 30, 2018

0

  • Previous
  • 1
  • 2
  • ...
  • 86
  • 87
  • 88
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy